Press Releases

Feb 15, 2022
Twist Bioscience Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Feb 10, 2022
Twist Bioscience Announces Pricing of an Upsized $250 Million Public Offering of Common Stock
Feb 10, 2022
Twist Bioscience to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
Feb 09, 2022
Twist Bioscience Announces Proposed Public Offering of Common Stock
Feb 08, 2022
C2i Genomics Partners with Twist Bioscience to Launch Reference Materials for Whole-Genome Cancer Detection
Feb 07, 2022
Twist Bioscience and Eleven Therapeutics Create Replicon for Development of Antiviral Tools
Feb 04, 2022
Twist Bioscience Reports First Quarter 2022 Financial Results
Feb 01, 2022
Abcam Collaborates With Twist Bioscience to Enhance Antibody Discovery for Diagnostic and Research Applications
Jan 31, 2022
Twist Bioscience Releases Inaugural ESG Report Highlighting Achievements and Initiatives in Diversity and Sustainability
Jan 25, 2022
Twist Bioscience Signs Collaboration with Artisan Bio to Engineer Next Generation Cell Therapeutics